CD274 and melanoma: In an ICI treatment targeting the PD-1/PD-L1 axis in melanoma patients, Response Evaluation Criteria in Solid Tumors (RECIST) were used to distinguish melanoma patients with or without a clinical response to ICI treatment, and they were labeled as responders or nonresponders.